Corrigendum to "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines" [Vaccine 34 (2016) 757-761]
1 Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium. Electronic address: pierre.vandamme@uantwerp.be.
2 Department of Health Sciences, University of Florence, Florence, Italy.
3 Cancer Research Epidemiology Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.
4 Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
5 Department of Gynaecology, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and the University of Copenhagen, Copenhagen, Denmark.
6 Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands.
7 Department of Gynaecology and Obstetrics, Klinikum Wolfsburg, Wolfsburg, Germany.
8 Sanofi Pasteur MSD, Department of Medical Affairs, Lyon, France.
9 P95, Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium.
10 Department of Pathology, Cambridge University, Cambridge, UK.